2021
DOI: 10.1182/hematology.2021000300
|View full text |Cite
|
Sign up to set email alerts
|

Acute GVHD: think before you treat

Abstract: The treatment of acute graft-versus-host disease (aGVHD) has become more nuanced in recent years with the development of improved risk classification systems and a better understanding of its complex, multisystem pathophysiology. We review contemporary approaches to the risk stratification and initial treatment of aGVHD, including ongoing clinical trials. We summarize the findings that led to the first US Food and Drug Administration approval for steroid-refractory aGVHD (SR-aGVHD), ruxolitinib, as well as som… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…The recommended in stage 2-3 with corticosteroids is 2 mg\kg\day systemic. [8][9][10] [11] [12] Recent clinical trellis defined corticosteroids failure as:…”
Section: Treatmentmentioning
confidence: 99%
“…The recommended in stage 2-3 with corticosteroids is 2 mg\kg\day systemic. [8][9][10] [11] [12] Recent clinical trellis defined corticosteroids failure as:…”
Section: Treatmentmentioning
confidence: 99%
“…It may also help to distinguish between potential acute GvHD flare-ups and other clinical conditions that might confuse the diagnosis (please refer to our case report for a pertinent, real-world clinical example). 16 However, further research is required to confirm these findings. In the future, circulating AREG should be studied in other T-cell inflammatory contexts to determine its specificity for acute GvHD activity versus other conditions.…”
mentioning
confidence: 97%